Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Rodent cell – per se
Reexamination Certificate
2001-06-29
2004-12-28
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Rodent cell, per se
C435S002000, C435S371000, C435S372000, C435S372100, C435S377000, C435S400000, C435S401000
Reexamination Certificate
active
06835566
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods for culturing lineage committed human cells, the cells thus obtained, and their uses.
2. Description of the Background
There is significant interest using both early and lineage committed cells for a variety of therapeutic purposes.
In tissue engineering, the goal is to reconstitute fully or partially functioning human tissue in vitro to enable a variety of clerical and other applications. Several studies have been carried out that are aimed at reconstituting functioning human tissues in vitro. Illustratively, the cultivation of human skin has been successful.
The hematopoietic system exemplifies the broad range of cells involved in protection of mammalian hosts against pathogens, toxins, neoplastic cells, and other diseases. The hematopoietic system is believed to evolve from a single stem cell, from which all the lineages of the hematopoietic system derive. Hematopoietic cells have been used in human therapy. Methods and apperati for culturing precursor hematopoietic cells to obtain desired mature hematopoietic cells have been described. See, U.S. Pat. Nos. 5,605,822, 5,399,493; 5,437,994; 5,459,069; 5,635,386, 5,670,147 and 5,670,351.
Adoptive cell therapy is the ex vivo expansion and re-infusion of immune effector cells into human recipients for the treatment or prevention of disease (Rosenberg et al., Science 233, 1318 (1986)). Developments in T-lymphocyte-based adoptive immunotherapy have lead to significant advances in the treatment of metastatic cancer (Rosenberg et al., Science 233, 1318 (1986); Rosenberg et al., N. Eng. J. Med. 319, 1676 (1988); Rosenberg et al., N. Eng. J. Med. 323, (1990)) and viral diseases including Epstein-Barr Virus (EBV) (Heslop et al. 1996), cytomegalovirus (CMV) (Riddell et al., Science 257, 238 (1992)) and human imunodeficiency virus (HIV) (Whiteside et al., Blood 81, 2085 (1993); Ridell et al., Hum. Gen. Ther. 3, 319 (1992)) in humans. Multiple patient populations have been identified in which T-cell therapy has achieved a response rate of approximately 34% after administration of tumor infiltrating lymphocytes (TILs) to metastatic melanoma patients (Rosenberg et al., J. Natl. Cancer Inst. 86, 1159 (1994)). A target human therapeutic dose of 10
10
-10
11
TLs is suggested based on extrapolation from studies in mouse tumor models and clinical experience (Topalian et al., J. Immunol. Meth. 102, 107 (1987)). Clinical responses to melanoma tumors have been obtained after expansion ex vivo of TILs in medium containing interleukin-2 (IL-2) and re-infusion of greater than 10
11
T-cells per treatment cycle together with high doses of exogenous IL-2 (Rosenberg et al., N. Eng. J. Med. 319, 1676 (1988); Rosenberg et al. 1994). The enhanced anti-tumor activity of TILs in vivo compared to lymphokine activated killer (LAK) cells or NK cells may be a function of several complex processes including the ability of these T-cells to proliferate and release an array of lymphokines, to recirculate and accumulate at sites of tumor growth, and to specifically recognize and lyse autologous tumor cells (Pockaj et al. 1994; Rosenberg et al. 1994).
Dendritic cells (DCs) are highly specialized bone-marrow derived antigen presenting cells (APCs) which function as potent stimulating cells for primary T-lymphocyte-mediated immune response. Dendritic cell based immunotherapy is an emerging treatment strategy involving ex vivo expansion and reinfusion of antigen-pulsed or genetically modified DCs into human patients to vaccinate against cancer or infectious diseases. Clinical implementation of these therapies requires the capability of product sufficient quantities of functional DCs for effective patient treatment.
The use of cultured human cells in human therapy has required that a quantity of active cells sufficient to provide a therapeutic effect upon infusion into the patient be used. This has required using culture systems providing large numbers of cells. There is therefore a need for methods for obtaining lineage committed cells with augmented proliferative potential, biological function, or both since such methods would provide more potent cell compositions, capable of being used in smaller amounts in therapy.
SUMMARY OF THE INVENTION
Accordingly, it is an object of this invention to provide novel methods, including culture media conditions, for obtaining human lineage committed cells with enhanced proliferative potential, biological function, or both.
It is another object of this invention to provide cultured human lineage committed cells having enhanced proliferative potential, biological function, or both.
These objects and others may be accomplished by a method for obtaining lineage committed human cells having enhanced proliferative potential, biological function, or both. In this method, lineage committed human cells are cultured in any physiologically acceptable liquid culture medium conditions with the liquid culture medium being replaced.
REFERENCES:
patent: 4135975 (1979-01-01), Lichtman et al.
patent: 4481946 (1984-11-01), Altshuler et al.
patent: 4486188 (1984-12-01), Altshuler et al.
patent: 4514499 (1985-04-01), Noll
patent: 4714680 (1987-12-01), Civin
patent: 4808611 (1989-02-01), Cosman
patent: 4810643 (1989-03-01), Souza
patent: 4847201 (1989-07-01), Kaswasaki et al.
patent: 4861714 (1989-08-01), Dean et al.
patent: 4889812 (1989-12-01), Guinn et al.
patent: 4963489 (1990-10-01), Naughton et al.
patent: 4965204 (1990-10-01), Civin
patent: 5004681 (1991-04-01), Boyse et al.
patent: 5032407 (1991-07-01), Wagner et al.
patent: 5032508 (1991-07-01), Naughton et al.
patent: 5061620 (1991-10-01), Tsukamoto et al.
patent: 5199942 (1993-04-01), Gillis
patent: 5399493 (1995-03-01), Emerson et al.
patent: 5605822 (1997-02-01), Emerson et al.
patent: 5635386 (1997-06-01), Palsson et al.
patent: 5646043 (1997-07-01), Emerson et al.
patent: 5670147 (1997-09-01), Emerson et al.
patent: 5670351 (1997-09-01), Emerson et al.
patent: 5674750 (1997-10-01), Kraus et al.
patent: 5728581 (1998-03-01), Schwartz et al.
patent: 5811094 (1998-09-01), Caplan et al.
patent: 5851832 (1998-12-01), Weiss et al.
patent: 5922597 (1999-07-01), Verfaillie et al.
patent: 5925567 (1999-07-01), Kraus et al.
patent: 5945225 (1999-08-01), Speith-Herfurth et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6299650 (2001-10-01), Van Blitterswijk et al.
patent: 6326198 (2001-12-01), Emerson et al.
patent: 0 358 506 (1990-03-01), None
patent: 0 455 482 (1991-11-01), None
patent: 90/15877 (1990-12-01), None
patent: 93/18136 (1993-09-01), None
patent: 93/18137 (1993-09-01), None
patent: 95/06409 (1995-03-01), None
Romani et al, Jour. Exper. Med., 180, 83-93, 1994.*
Siena et al, Exper. Hematol., 23, 1463-1471, 1995.*
M. W. Glacken et al., “Mammalian cell culture: engineering principles and scale-up”, Trends in Biotechnology, vol. 1, No. 4, 1983, pp. 102-108.
Steven A. Rosenberg et al., “In Vitro Growth of Murine T Cells II. Growth of In Vitro Sensitized Cells Cytotoxic for Alloantigens”, The Journal of Immunology, vol. 121, No. 5. Nov. 1978, pp. 1951-1955.
W. French Anderson, “Prospects for Human Gene Therapy”, Science, vol. 26, Oct. 26, 1987, pp. 401-409.
T.M. Dexter, “The Message in the medium”, Nature, vol. 309, Jun. 1984, pp 746-747.
Manfred R. Koller, et al. “Expansion of Primitive Human Hematopoietic Progenitors in a Perfusion Bioreactor System with LL-3, LL-6, and Stem Cell Factor”, Biotechnology, vol. 11, Mar., 1993, pp. 358-363.
Bernhard O. Palsson et al, “Expansion of Human Bone Marrow Progenitor Cells in a High Cell Density Continuous Perfusion System”, Biotechnology, vol. 11, Mar., 1993, pp. 368-372.
Giovanni Migliaccio et al., “In Vitro Differentiation of Human Granulocyte/Macrophage and Erythroid Progenitors: Comparative Analysis of the Influence of Recombinant Human Erythropoietin, G-CSF, GM-CSF, and IL-3 in Serum-Supplemented and Serum-Deprived Cultures”, Blood, vol. 72, No. 1 Jul. 1988, pp. 248-255.
Ian K. McNiece et al., “Studies on the Myeloid Synergistic Factor From 563
Mandalam Ramkumar K.
Smith Alan K.
Smith Douglas M.
Aastrom Biosciences, Inc.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Saunders David
LandOfFree
Human lineage committed cell composition with enhanced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human lineage committed cell composition with enhanced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human lineage committed cell composition with enhanced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3330065